P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial — Meletios A Dimopoulos (2021) | RDL Network
Meletios A Dimopoulos, Katja Weisel, Sagar Lonial, Darrell White, Philippe Moreau, María‐Victoria Mateos, Jesús F. San Miguel, Kenneth C. Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Alex Ganetsky, Ying‐Ming Jou, Mihaela Popa McKiver, Anil Singhal, Paul G. Richardson
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, David Yao, Prianka Das, Jesús F. San Miguel
Katja Weisel, Meletios A Dimopoulos, Jesús F. San Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord‐Bessen, Christine Yip, Mike Greenwood, Jackson Tang, Michèle Cavo
Katja Weisel, Meletios A Dimopoulos, Jesús F. San Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord‐Bessen, David Yao, Christine Yip, Mike Greenwood, Jackson Tang, Michèle Cavo
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kazuyuki Suzuki, Marc‐Steffen Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, Suresh G. Shelat, Michael Robbins, B. Rafferty, Jesús F. San Miguel
Discussion(0)
No comments yet. Be the first to comment.